Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and ImageneBio (NASDAQ:IMA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Institutional and Insider Ownership
1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Creative Medical Technology and ImageneBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
| ImageneBio | 2 | 0 | 1 | 1 | 2.25 |
Profitability
This table compares Creative Medical Technology and ImageneBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
| ImageneBio | N/A | -38.99% | -34.84% |
Earnings and Valuation
This table compares Creative Medical Technology and ImageneBio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $10,000.00 | 586.51 | -$5.99 million | ($2.07) | -0.43 |
| ImageneBio | $800,000.00 | 65.40 | -$45.35 million | ($4.58) | -1.01 |
Creative Medical Technology has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Creative Medical Technology has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Summary
ImageneBio beats Creative Medical Technology on 8 of the 13 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About ImageneBio
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
